
Forest Devices, Inc.
Developing AlphaStroke that's the first stroke screening device designed for use by medical personnel in any environment.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor | €0.0 | round |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor investor investor investor investor investor investor | €0.0 | round | |
N/A | Seed | ||
Total Funding | 000k |
Related Content
Forest Devices is a pioneering medical technology company focused on revolutionizing stroke diagnosis and treatment in the prehospital setting. The company has developed an innovative, electronically determined test for stroke, specifically designed for use by Emergency Medical Services (EMS). This technology aims to address the critical issue of stroke misdiagnosis, which affects 30-50% of the 4 million stroke exams performed annually by first responders. Misdiagnosis often leads to significant delays in treatment, with major stroke patients experiencing a median delay of 110 minutes, drastically reducing the likelihood of receiving the most effective treatment by 90%.
Forest Devices' solution has demonstrated a 92% increase in diagnostic accuracy in pilot clinical trials involving nearly 300 participants. This advancement is expected to significantly reduce disabilities, rehabilitation costs, and even fatalities associated with stroke. Additionally, it aims to minimize hospital reimbursement losses by ensuring timely and appropriate stroke treatment.
The company operates in the healthcare technology market, primarily serving EMS providers and hospitals. Its business model revolves around selling its diagnostic devices and related software to these clients, generating revenue through direct sales and potential service agreements.
Keywords: stroke diagnosis, EMS technology, prehospital care, medical device, healthcare innovation, diagnostic accuracy, patient outcomes, treatment delays, clinical trials, hospital reimbursement.